John Snisarenko Net Worth

The estimated Net Worth of John Snisarenko is at least $2.11 million dollars as of 10 August 2020. Mr. Snisarenko owns over 4,000 units of Oyster Point Pharma Inc stock worth over $78,190 and over the last 5 years he sold OYST stock worth over $0. In addition, he makes $2,028,190 as Chief Commercial Officer at Oyster Point Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Snisarenko OYST stock SEC Form 4 insiders trading

John has made over 3 trades of the Oyster Point Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of OYST stock worth $103,880 on 10 August 2020.

The largest trade he's ever made was buying 10,000 units of Oyster Point Pharma Inc stock on 21 November 2019 worth over $49,500. On average, John trades about 1,417 units every 23 days since 2019. As of 10 August 2020 he still owns at least 7,000 units of Oyster Point Pharma Inc stock.

You can see the complete history of Mr. Snisarenko stock trades at the bottom of the page.

John Snisarenko biography

John Snisarenko serves as Chief Commercial Officer of the Company. Mr. Snisarenko was most recently the Group Vice President of the Ophthalmology Business Unit at Takeda Pharmaceuticals (previously Shire) from June 2017 to September 2019. Prior to joining Shire, Mr. Snisarenko was a Vice President in Genentech’s ophthalmology business units from December 2007 until May 2017. From April 2006 to December 2007, Mr. Snisarenko was a Vice President in the ophthalmology business of NOVADAQ Technologies and from June 1996 to April 2006, he was a Vice President in the ophthalmology business of Novartis Pharmaceuticals Canada. Mr. Snisarenko has been a member of the board of directors of Alimera Sciences, Inc. (Nasdaq:ALIM) since July 2019. Mr. Snisarenko received a B.Sc. in Biochemistry and an M.B.A. from McGill University.

What is the salary of John Snisarenko?

As the Chief Commercial Officer of Oyster Point Pharma Inc, the total compensation of John Snisarenko at Oyster Point Pharma Inc is $2,028,190. There are 1 executives at Oyster Point Pharma Inc getting paid more, with Jeffrey Nau having the highest compensation of $4,037,700.

How old is John Snisarenko?

John Snisarenko is 57, he's been the Chief Commercial Officer of Oyster Point Pharma Inc since 2019. There are 2 older and 3 younger executives at Oyster Point Pharma Inc. The oldest executive at Oyster Point Pharma Inc is William Link, 74, who is the Independent Director.

What's John Snisarenko's mailing address?

John's mailing address filed with the SEC is 6310 TOWN SQUARE, SUITE 400, ALPHARETTA, GA, 30005.

Insiders trading at Oyster Point Pharma Inc

Over the last 5 years, insiders at Oyster Point Pharma Inc have traded over $24,486,000 worth of Oyster Point Pharma Inc stock and bought 3,552,871 units worth $59,028,668 . The most active insiders traders include Ali Behbahani, Venture Capital Vi, L.P.Ver... et Clare Ozawa. On average, Oyster Point Pharma Inc executives and independent directors trade stock every 27 days with the average trade being worth of $2,204,444. The most recent stock trade was executed by Daniel Lochner on 1 November 2021, trading 8,590 units of OYST stock currently worth $98,871.

What does Oyster Point Pharma Inc do?

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.

Complete history of Mr. Snisarenko stock trades at Alimera Sciences et Oyster Point Pharma Inc

Oyster Point Pharma Inc executives and stock owners

Oyster Point Pharma Inc executives and other stock owners filed with the SEC include:

• Jeffrey Nau,
  President, Chief Executive Officer, Director
• John Snisarenko,
  Chief Commercial Officer
• Daniel Lochner,
  Chief Financial Officer
• Dr. Jeffrey Nau Ph.D., MMS,
  Pres, CEO & Director
• Daniel Lochner M.B.A.,
  Chief Financial Officer
• John Snisarenko M.B.A.,
  Chief Commercial Officer
• Mark Murray,
  Director
• Ali Behbahani,
  Chairman of the Board
• Benjamin Tsai,
  Independent Director
• Aimee Weisner,
  Independent Director
• William Link,
  Independent Director
• Clare Ozawa,
  Independent Director
• Tim McCarthy,
  IR Contact Officer
• Michael Atieh,
  Director
• Dr. Marian Macsai M.D.,
  Chief Medical Officer of Medical Affairs
• Loni Da Silva M.S.,
  Sr. VP of Regulatory Affairs
• Raegan A. McClain CCEP, J.D., L.L.M.,
  Chief Compliance Officer
• Barry Rosenfeld J.D.,
  Sr. VP & Gen. Counsel
• Dr. Eric Carlson Ph.D.,
  Chief Scientific Officer
• George Donato M.B.A.,
  Sr. VP of CMC & Operations
• Ventures, Llc Vida,
  10% owner
• Point Pharma I, Llc Oyster,
  10% owner
• Vision Llckkr Healthcare St...,
  
• Gp Iv, L.L.C.Inv Opps Iv, L...,
  
• Michael Ackermann,
  Director
• Perkins Caufield & Byers Xi...,
  
• Venture Capital Vi, L.P.Ver...,
  
• Fund Holdings L.P.Kravis He...,
  
• George Christopher Eliades,
  Director
• Donald J Santel,
  Director
• Enterprise Associates 14, L...,